Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts

Overview of attention for article published in Cancer Discovery, February 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 5 news stories from 5 outlets.

Featuring insights into AML treatments, translational models for drug development, a novel role for p53, and therapeutic…

HOUSTON ― The University of Texas MD Anderson Cancer Center's Research Highlights showcases the latest breakthroughs in cancer…

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer…

Post Views: 1 HOUSTON ― The University of Texas MD Anderson Cancer Centers Research Highlights showcases the latest…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 1 additional news stories.